Jeffrey Nugent, MD
Allergy & Immunology · Reno, NVNPI 1871572768
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 491 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations.
Across 491 payments — averaging $24.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- AstraZeneca$1K
- GSK$1K
- CSL Behring$787
- Pharming Healthcare, Inc.$495
- plus $5K from 32 others
What the payments were for
- Consulting fees$420%
- Food & beverage$11,47897%
- Education$3513%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 48 | $1,669 |
| Takeda Pharmaceuticals U.S.A., Inc. | 64 | $1,489 |
| AstraZeneca | 50 | $1,312 |
| GSK | 66 | $1,259 |
| CSL Behring | 37 | $787 |
| Pharming Healthcare, Inc. | 17 | $495 |
| Novartis | 22 | $454 |
| Genentech USA, Inc. | 7 | $440 |
| Blueprint Medicines Corporation | 9 | $406 |
| Biocryst US Sales Co., LLC | 13 | $344 |
| Boehringer Ingelheim | 23 | $300 |
| Greer Laboratories, Inc. | 8 | $264 |
| Optinose US, Inc. | 12 | $246 |
| Sanofi | 13 | $224 |
| Kaleo, Inc. | 11 | $212 |
| Octapharma USA, Inc. | 12 | $210 |
| Pfizer | 9 | $205 |
| Bio Products Laboratory USA, Inc. | 9 | $154 |
| Cycle Pharmaceuticals Inc | 6 | $151 |
| Grifols USA, LLC | 7 | $148 |
| Genentech, Inc. | 2 | $146 |
| Teva Pharmaceuticals USA, Inc. | 11 | $143 |
| Amgen(2 entities) | 6 | $128 |
| Shire North American Group Inc | 7 | $128 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Alk-abello, Inc | 3 | $60 |
| Aimmune Therapeutics, Inc. | 2 | $52 |
| LEO Pharma Inc. | 2 | $50 |
| Lilly USA, LLC | 2 | $47 |
| ADMA Biomanufacturing LLC | 2 | $42 |
| Insmed, Inc. | 2 | $41 |
| Kedrion Biopharma, Inc. | 2 | $36 |
| Ionis Pharmaceuticals, Inc. | 1 | $35 |
| Hospira, Inc. | 1 | $26 |
| Hikma Pharmaceuticals USA | 1 | $23 |
| Merck | 1 | $18 |
| AbbVie | 1 | $16 |
| USWM, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy & immunology providers in Nevadato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 67 | $259,836 |
| XolairOmalizumab | 25 | $72,619 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $29,271 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $28,771 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $13,307 |
| Spiriva RespimatTiotropium Bromide | 12 | $9,321 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 51 | $6,403 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $5,725 |
| Epinephrine | 29 | $5,580 |
| Atrovent HfaIpratropium Bromide | 12 | $5,401 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $4,238 |
| BreynaBudesonide/Formoterol Fumarate | 14 | $3,809 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $3,661 |
| Azelastine Hcl | 90 | $1,957 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 90 | $1,757 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $146 | $72,61925 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $1,259 | $58,04268 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,312 | $19,03140 claims |
| Boehringer IngelheimSpiriva Respimat | $300 | $9,32112 claims |
| Hikma Pharmaceuticals USAEpinephrine | $23 | $5,58029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in Nevadaon file to place this against a meaningful peer group, so we don't.
Other allergy & immunology in Reno
- Reece JonesReno$9K
- Donald BlackReno$63
- Jason BellakLas Vegas$41K
- Ricardo VinuyaLas Vegas$36K
- Frederick HermanHenderson$35K
- Matt MorganLas Vegas$12K
- Anthony NguyenLas Vegas$9K
- Andrew McKnightHenderson$8K
- Sandy YipHenderson$5K
- Bob MiyakeHenderson$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.